Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04245722
Title FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fate Therapeutics

B-cell lymphoma

chronic lymphocytic leukemia


Cyclophosphamide + Fludarabine + FT596 + Obinutuzumab

Cyclophosphamide + Fludarabine + FT596

Cyclophosphamide + Fludarabine + FT596 + Rituximab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
The University of Chicago Recruiting Chicago Illinois 60637 United States Details
University of Minnesota Masonic Cancer Center Recruiting Minneapolis Minnesota 55455 United States Details
Washington University School of Medicine Recruiting Saint Louis Missouri 63110 United States Details
NYU Langone Health Recruiting New York New York 10016 United States Details
Memorial Sloan Kettering Cancer Center Recruiting New York New York 10065 United States Details
Sarah Cannon Research Institute (Tennessee Oncology) Recruiting Nashville Tennessee 37203 United States Details
MD Anderson Cancer Center Recruiting Houston Texas 77030 United States Details
SCRI-TTI Recruiting San Antonio Texas 78229 United States Details
Swedish Cancer Institute Recruiting Seattle Washington 98104 United States Details
*Shaded cells indicate that there was no data available from for the field